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Introduction 45
In the last five to ten years, the incidence of infections caused by Enterobacteriaceae 46 producing extended-spectrum -lactamase (ESBL) has increased rapidly and was mainly 47
Results

121
During the 24-month study period, there were a total of 857 adult patients with a 122 positive blood culture for E. coli. Of these, 207 (24.2%) patients had ESBL-EC bacteremia. 123
Two patients were excluded because the clinical records were not available for review and 124 one patient was excluded because antimicrobial was not given before death. Therefore, 204 125 patients were included in this study (Table 1) . Overall, 8.3% (17/204) and 91.7% (187/204) 126 of the patients were classified as having community-associated and hospital-associated 127 infections respectively. Among the hospital-associated infections, 32.1% (60/187) were 128 classified as hospital onset, 38.5% (72/187) were RCHE residents and 89.8% (168/187) had 129 prior hospitalization within 1 year. More than two-thirds of the patients were aged 65 years or 130 above. At the time of blood culture collection, more than 50% of patients were located in the 131 medical ward. Urinary tract (43.6%) was the most common source of infection, followed by 132 the hepatobiliary tract (23.0%). 133 134 Table 2 shows the result of the susceptibility testing. All strains were susceptible to 135 imipenem. Over 90% of the strains were susceptible to piperacillin-tazobactam or amikacin. 136
137
The use of antibiotics is illustrated in Figure 1 Our study showed that a high proportion of patients with ESBL-EC bacteremia 183 received initial therapy which was considered to be inappropriate because many of them 184 involved agents with little in-vitro activity or uncertain efficacy against the infecting 185 organisms. In most patients, such "inappropriate" (i.e. discordant) therapy lasted two to three 186 days. Our findings showed that this had little effect on patient mortality and the length of stay 187 in hospital. In addition to the relatively short duration of inappropriate therapy, there were 188 other possible explanations for our findings. The prevalence of ESBL-EC strains among E. coli bacteremia (24.2%) in our study 208 was higher than those reported in other studies conducted during the same period 22, 23 . In our 209 previous study, the incidence density of ESBL-EC bacteremia has increased from 8.6 per 210 100,000 patient-days in year 2000-2005 to 16.9 per 100,000 patient-days in year 2006-2010 8 . 211
Previously identified risk factors for ESBL-producers included healthcare associations such 212 as RCHE residency and hospital onset bacteremia, recent use of antibiotics, comorbidities, 213 presence of gastrostomy tubes or urinary catheters, and urinary tract infections [24] [25] [26] . The 214 baseline characteristics of our study cohort concur with these known risk factors. We have 215 also found that 8.3% of patients with ESBL-EC bacteremia were community associated. The 216 prevalence of community-acquired infections has been increasing, and one study in India 217
showed that up to 46% of Enterobacteriaceae strains from outpatients were ESBL-producer 218 27 . The increase in community-acquired ESBL-EC infection parallels with the increasing 219 carriage of ESBL-EC in the community. In Hong Kong, stool carriage of ESBL-producing 220 organisms was found in 43.5% in the children who were admitted for respiratory tract 221 infection and their household members 28 . The rate of ESBL-producers in urine collected 222 from women in the community now exceeds >5% 6, 29 . It has been postulated that an increase 223 in ESBL-EC in the community is due to the high rate of antibiotic resistance in food animals 224 30 . In our locality, there is a high fecal carriage rate of ESBL-EC in food animals, exceeding 225 60% in live pigs and chickens 5 . Since ESBL-EC bacteremia results in high mortality as 226 shown in the current study (21.6%), controlling the incidence and spread of ESBL-EC in the 227 community would be very important. 228 229 Over 90% of our isolates were susceptible to piperacillin-tazobactam. The 230 piperacillin-tazobactam susceptible rate in our cohort was higher than that reported in other 231 12 studies 31, 32 . To a certain extent, such variations in susceptibility reflect differences in the 232 major clonal types and ESBL enzymes. In Hong Kong, the CTX-M-9 group and CTX-M-14 233 allele were the predominat ESBL type 3 . Among the patients in the present study, the 234 sequence type (ST) was determined for the isolates from 116 randomly selected patients, 235 among which 30 patients (25.9%) had infection by E. coli belonging to ST131. The 236 remaining isolates included 5 ST69, 3 ST12, 3 ST68 and 75 singletons 3 . In our study, we 237 have also found a low susceptibility rate to levofloxacin. This is of particular concern, as 238 
